Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies.

Rheumatology (Oxford, England) - 1 Sept 2024

Tian Xueke, Liu Lijun, Liu Shengyun, Yang Jing

Abstract excerpt

OBJECTIVE: Idiopathic inflammatory myopathies (IIM) are a heterogeneous and life-threatening group of diseases; in particular, anti-melanoma differentiation-associated gene 5 antibody positive DM (MDA5+ DM) is reportedly strongly associated with high mortality rate. Tacrolimus (TAC) provides an excellent therapeutic option, but the trough concentration (Cmin)-outcome relationship remains unexplored. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to China
Share to Cytochrome P-450 CYP3A
Share to East Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Myositis

Share to Precision Medicine

Share to Recurrence

Share to Tacrolimus

Source

Identifiers

PMID: 38889292
DOI: 10.1093/rheumatology/keae316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies.PMID 38889292Read ↗

HLA-A*11:01 and HLA-C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups.Semantic proximity Read ↗

Population Pharmacokinetics and Dose Optimization of Tacrolimus in Chinese Adult Patients with Myasthenia GravisSemantic proximity Read ↗

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.Semantic proximity Read ↗

Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.Semantic proximity Read ↗

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.Semantic proximity Read ↗

A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMETTM Plus Platform.Semantic proximity Read ↗

Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies.Semantic proximity Read ↗

Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases.Semantic proximity Read ↗

Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity Read ↗

Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease.Semantic proximity Read ↗

Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.Semantic proximity Read ↗

Treatment of Interstitial Lung Disease In Anti-MDA5-Positive Dermatomyositis: A Retrospective Study of 87 PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.